Symbol
| GAPDH
| contributors: mct/shn - updated : 22-08-2017
|
HGNC name
| glyceraldehyde-3-phosphate dehydrogenase
|
HGNC id
| 4141
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
| amplification
|  
|  
|
in Huntington disease (high molecular weight protein) | tumoral
|  
|  
| --over
|  
|
in gastric cancer | tumoral
|  
| translocation
|  
|  
|
with BCL6 in primary diffuse large B-cell lymphomas of the central nervous system | tumoral
|  
|  
| --over
|  
|
overexpressed in renal cell carcinoma | constitutional
|  
|  
| --over
|  
|
in apoptosis and in several chronic pathologies | |
Susceptibility
|
to late-onset Alzheimer disease |
Variant & Polymorphism
SNP
| SNP increasing the risk of late-onset Alzheimer disease |
|
|
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
diabete | | | |
agents that can directly target modification of GAPDH have potential in inhibiting the development and in arresting the progression of diabetic retinopathy | cancer | digestive | pancreas | |
double blockade of GAPDH and mitochondrial respiration could be a novel strategy for the treatment of PRMT3-overexpressing pancreatic cancer |
| | | |